definiens: means ( i ) KGT-1650 ( remogliflozin ) and KGT-1681 ( remogliflozin etabonate ), and ( ii ) if a ( as defined in the Kissei Agreement ) has occurred pursuant to Section 2.02 of the Kissei Agreement, thecompounds with the internal Kissei code names of KGT-1251 and KGT-1075 and such other compounds included in theKissei Patents, or discovered, invented or generated by Kissei with SGLT2 selective inhibitory effect as their primarymechanism of pharmacological activity within the scope of clause ( i ) of the definition in this Agreement ( butexcluding compounds with effects on proteins other than SGLT2 selective inhibitory effect as their primary mechanismof pharmacological activity ), in all formulations, and all prodrugs, metabolites, salts, hydrates, solvates, polymorphs, enantiomers and isomers thereof